Neo Ivy Capital Management’s ADMA Biologics ADMA Stock Holding History

Neo Ivy Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.8M	Buy	199,687 +130,545	+189%	+$2.06M	0.47%	82
2025 Q4	$1.26M	Buy	69,142 +60,302	+682%	+$1.02M	0.2%	156
2025 Q3	$130K	Buy	+8,840	New	+$152K	0.03%	316
2025 Q2	–	Sell	-20,944	Closed	-$416K	–	348
2025 Q1	$416K	Sell	20,944 -276,683	-93%	-$4.79M	0.13%	203
2024 Q4	$5.1M	Buy	297,627 +249,043	+513%	+$4.69M	1.03%	15
2024 Q3	$972K	Buy	+48,584	New	+$756K	0.31%	121

Other funds holding ADMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Neo Ivy Capital Management's ADMA Position: Q1 2026 in Review

Neo Ivy Capital Management increased its ADMA Biologics (ADMA) stake by 189% in Q1 2026, buying an estimated $2.06M and bringing the position to 199,687 shares worth $1.8M. The position accounts for 0.47% of the portfolio, ranked #82.

Neo Ivy Capital Management first reported a position in ADMA in Q3 2024 and has held it in 6 quarters since. The position peaked at $5.1M in Q4 2024. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

Neo Ivy Capital Management held 199,687 shares of ADMA Biologics worth $1.8M as of Q1 2026.
Neo Ivy Capital Management bought 130,545 ADMA Biologics shares in Q1 2026, an estimated $2.06M.
ADMA Biologics made up 0.47% of Neo Ivy Capital Management's portfolio in Q1 2026, its #82 holding.
Neo Ivy Capital Management first reported a position in ADMA Biologics in Q3 2024 and has held it in 6 quarters since.
Neo Ivy Capital Management's ADMA Biologics position peaked at $5.1M in Q4 2024.
356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Neo Ivy Capital Management's 13F filing for Q1 2026, filed 15 May 2026.